April, 2025
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
282930  
Kristina Jankovic: FDA approved datopotamab, deruxtecan-dlnk for unresectable, metastatic, HR+ HER2- breast cancer
Jan 20, 2025, 13:56

Kristina Jankovic: FDA approved datopotamab, deruxtecan-dlnk for unresectable, metastatic, HR+ HER2- breast cancer

Kristina Jankovic, Medical Oncology Resident at University Clinical Center Nis, shared a post on X:

“DC Approval!! US FDA approved datopotamab, deruxtecan-dlnk for unresectable, metastatic, HR+ HER2- Breast Cancer previously treated with endocrine and chemotherapy for unresectable, metastatic disease. ”

Kristina Jankovic: FDA approved datopotamab, deruxtecan-dlnk for unresectable, metastatic, HR+ HER2- breast cancer

Additional Information